Acquired Hemophilia A

Rare Diseases
3
Pipeline Programs
2
Companies
8
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
2
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 6 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
6 programs
2
OBI-1Phase 2/31 trial
TAK-672Phase 2/31 trial
OBI-1N/A1 trial
OBIZURN/A2 trials
OBIZURN/A1 trial
+1 more programs
Active Trials
NCT01968655No Longer Available
NCT06550882Recruiting9Est. Sep 2026
NCT03199794Completed50Est. Jul 2021
+4 more trials
Genentech
GenentechCA - Oceanside
1 program
1
emicizumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT05345197Active Not Recruiting51Est. Dec 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
TakedaTAK-672
TakedaOBI-1
Genentechemicizumab
TakedaOBIZUR
TakedaSusoctocog Alfa
TakedaOBIZUR
TakedaOBIZUR

Clinical Trials (8)

Total enrollment: 222 patients across 8 trials

NCT04580407TakedaTAK-672

Study of TAK-672 in Participants With Acquired Hemophilia A

Start: Apr 2021Est. completion: Nov 20225 patients
Phase 2/3Completed
NCT01178294TakedaOBI-1

Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A

Start: Nov 2010Est. completion: Oct 201329 patients
Phase 2/3Completed
NCT05345197Genentechemicizumab

Emicizumab in Patients With Acquired Hemophilia A

Start: Aug 2022Est. completion: Dec 202651 patients
Phase 2Active Not Recruiting
NCT01968655TakedaOBI-1

Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies

N/ANo Longer Available
NCT06550882TakedaOBIZUR

A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea

Start: Jul 2025Est. completion: Sep 20269 patients
N/ARecruiting
NCT06461533TakedaSusoctocog Alfa

A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A

Start: Jun 2024Est. completion: Oct 202925 patients
N/ARecruiting
NCT03199794TakedaOBIZUR

Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice

Start: Dec 2016Est. completion: Jul 202150 patients
N/ACompleted
NCT02610127TakedaOBIZUR

Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A

Start: Dec 2015Est. completion: Jun 201953 patients
N/ACompleted

Related Jobs in Rare Diseases

Manager, Gene Therapy Operations (GTO)

Genetix Biotherapeutics
8h ago
From $130K/yr

Manager, Gene Therapy Operations (GTO)

Genetix Biotherapeutics
Somerville, Massachusetts, United States
8h ago

Medical Engagement Manager – Diamyd Medical

Bonesupport
Stockholm, Sweden
Yesterday

Exec. Director, Global Patient Engagement

BioCryst Pharmaceuticals
US_North Carolina_Headquarters
Yesterday

Sr. Director, Regulatory CMC

Genetix Biotherapeutics
Somerville, MA
4d ago
From $270K/yr

Associate Director, Quality Systems

Genetix Biotherapeutics
Somerville, Massachusetts
4d ago
From $165K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 222 patients
2 companies competing in this space

Related Indications

Cystic Fibrosis(244)Hemophilia A(139)Sickle Cell Disease(64)Fabry Disease(55)Duchenne Muscular Dystrophy(53)Hemophilia B(47)Spinal Muscular Atrophy(34)Phenylketonuria(32)Gaucher Disease(29)Severe Hemophilia A(26)